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Abstract
Background: The standard care in patients with a painful osteoporotic vertebral compression
fracture (VCF) is conservative therapy. Percutaneous vertebroplasty (PV), a minimally invasive
technique, is gaining popularity as a new treatment option. Many prospective and retrospective
studies have reported on the effectiveness and safety of PV, but no large randomized controlled
trial (RCT) has been published.
Objective: To estimate cost-effectiveness of PV compared to conservative therapy in terms of:
pain reduction, quality of life, complications, secondary fractures and mortality.
Materials and methods: The VERTOS II study is designed as a prospective, multicenter RCT.
Patients with a painful VCF with bone edema on MR imaging, local back pain for 6 weeks or less,
osteopenia and aged 50 years or older, after obtaining informed consent are included and
randomized for PV or conservative therapy. In total 200 patients will be enrolled. Follow-up is at
regular intervals during a 1-year period with standard questionnaires, addressing: clinical symptoms,
pain medication, Visual Analogue Scale (VAS) score, quality of life and cost-effectiveness. Secondary
fractures, necessary additional therapies and complications are recorded.
Published: 31 October 2007
Trials 2007, 8:33 doi:10.1186/1745-6215-8-33
Received: 12 April 2007
Accepted: 31 October 2007
This article is available from: http://www.trialsjournal.com/content/8/1/33
© 2007 Klazen et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
Trials 2007, 8:33 http://www.trialsjournal.com/content/8/1/33Conclusion: The VERTOS II study is the first methodologically sound RCT designed to assess the
cost-effectiveness of PV compared to conservative therapy in patients with an acute osteoporotic
VCF.
Trial registration: http://www.clinicaltrials.gov, NCT00232466
Introduction
Because of an aging population osteoporosis and associ-
ated fractures are becoming an important health issue,
especially in Western societies. The incidence of a new ver-
tebral compression fracture (VCF) in Europe is, at age 50–
79 years, 1% per year in women and 0,6% per year in men
and at age 75–79 years the incidence is 2,9% per year in
women and 1,4% per year in men [1]. VCFs are associated
with an increased incidence of mortality and morbidity,
including back pain, loss of height, kyphotic deformity
and a reduction in quality of life (QOL) [2].
Conservative therapy, bed rest, pain medication, physio-
therapy and bracing, is considered the standard care in
patients with symptomatic osteoporotic VCFs. Since the
introduction of percutaneous vertebroplasty (PV) this
minimal invasive therapy has gained popularity to stabi-
lize osteoporotic VCFs and subsequently relief of associ-
ated local back pain. Despite the apparent lack of
evidence, nowadays PV is considered an accepted therapy
in many centres and acknowledged as a useful additional
option in the care for these patients.
In 1984 PV was developed in France for the treatment of
painful aggressive vertebral angioma [3]. In the following
years the indications for PV were expanded to vertebral
fractures caused by osteoporosis, trauma, malignant or
benign vertebral tumors and vertebral osteonecrosis. Pres-
ently, PV is most frequently performed to treat patients
with painful osteoporotic VCFs.
Numerous prospective and retrospective studies on PV
have been published and described a high clinical success
rate [4-12]. A recent systematic literature review demon-
strated the effectiveness of PV in 87% of patients in terms
of pain relief as well as a short- and long-term improve-
ment of function [13]. However, these studies did not
have a control group to compare with. In fact we do not
know what would have been the natural course of pain in
similar patients with a VCF. Only two non-randomised
controlled trials have been published comparing PV with
conservative therapy [14,15]. Both studies demonstrated a
significant better improvement in pain scores after PV
compared to conservative therapy on the short-term.
However, after 6 months no differences could be demon-
strated. Thus, the question on the balance between costs
and effects becomes all the more pregnant.
VERTOS, the first randomized controlled trial (RCT) with
a limited group of 34 patients reports only on short-term
results [16]. Longer term results could not be obtained
due to the cross-over of many patients from the optimal
pain medication (OPM) group to the PV group already
after two weeks follow-up. VERTOS confirmed immediate
pain relief and improvement of mobility, function and
stature after PV. The short-term results after PV were sig-
nificantly better compared to OPM in these patients with
sub-acute or chronic osteoporotic VCFs.
The development of new VCFs after PV in patients with
osteoporosis is, in addition to pain relief and function,
another important issue. It remains unclear whether PV is
associated with a higher risk of secondary VCFs in adja-
cent vertebral bodies. Some authors believe in an
increased risk of new VCFs after PV compared to the natu-
ral fracture incidence in osteoporosis, probably initiated
by the increased stiffness of the cementated vertebral body
[17-19]. The non-randomized study by Diamond
reported no significant difference in the risk of new VCFs
between PV and conservative therapy [14].
Even now, after decades of performing PV no large RCT
with mid-term follow-up has been published. Therefore,
the VERTOS II study, a new RCT, was initiated to compare




To estimate cost-effectiveness of PV compared to conserv-
ative therapy in terms of: pain reduction, QOL, complica-
tions, secondary fractures and mortality.
Study design
VERTOS II is a multicenter RCT concerning the treatment
of patients with a painful osteoporotic VCF. Patients are
randomized to: (i) conservative therapy consisting of
OPM, osteoporosis medication, physiotherapy or bracing;
or (ii) PV with osteoporosis medication and analgesics, if
necessary. Upon obtaining informed consent an inde-
pendent central telephone operator completes the ran-
domisation procedure, using a computer programme. The
maximum allowed unbalance (block size) is six, with a
maximum sample size of 84 for each participating centre.
A total of 200 patients will be enrolled, 100 in each group.
The enrolment of patients takes place in five centres: fourPage 2 of 5
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University Medical Centre Utrecht, Diakonessenhuis
Utrecht/Zeist/Doorn, Catharina Hospital Eindhoven) and
one in Belgium (AZ St. Lucas Hospital Gent). Randomiza-
tion started November 2005 with an expected completion
of enrolment by March 2008. There is a one-year follow-
up, with the possibility of an extended follow-up at two
years. At present a total number of 111 patients is
included.
The overall Institutional Review Board approval was
obtained at the St. Elisabeth Hospital in Tilburg. Each par-
ticipating centre also obtained a local Institutional Review
Board Approval. This study was registered in September
2005 at ClinicalTrials.gov [20].
Patients
All patients, 50 years of age or older, visiting the hospital
for an X-ray of the thoracic and/or lumbar spine, receive a
short clinical questionnaire. Patients diagnosed with a
VCF (Th5-L5), pain for six weeks or less and a Visual Ana-
logue Scale (VAS) score of five and higher are contacted to
participate in the study.
After informed consent patients undergo a magnetic reso-
nance imaging (MRI) scan of the spine, bone densitome-
try, blood sample screening and will visit the internist.
All patients enrolled in the study comply with the follow-
ing inclusion criteria: (1) VCF on X-ray of the spine (min-
imal 15% loss of height), (2) level of VCF Th5 or lower,
(3) back pain ≤ 6 weeks at time of X-ray, (4) ≥ 50 years of
age, (5) bone edema on MRI of the fractured vertebral
body, (6) focal tenderness on VCF level and (7) decreased
bone density T-scores ≤ -1. The exclusion criteria are: (1)
severe cardio-pulmonary condition, (2) untreatable coag-
ulopathy, (3) systemic or local infection of the spine
(osteomyelitis, spondylodiscitis), (4) indication of alter-
native underlying disease (malignancy) and (5) radicular
and/or myelum compression syndrome. All patients con-
tacted to participate in the study are registered in order to
obtain an overview of the total patient population.
MRI protocol
MRI is performed in all patients prior to randomization
using a 1 or 1,5 Tesla MRI scanner. The following MRI
sequences are employed: sagittal T1 (TR 400 ms, TE 13
ms), T2 Turbo Spin Echo (TR 3500 ms, TE 120 ms) and
STIR (TR 2500 ms, TE 70 ms) and transverse T2 TSE (TR
2500 ms, TE 120 ms) at the level of the affected VCF. Bone
edema in the VCF is defined as increased signal intensity
at the STIR images and decreased signal intensity at the T1
weighted images. The shape and grade of every VCF is
scored by two radiologists using the visual semiquantita-
tive system according to Genant [21]. When there is disa-
greement between both observers a consensus meeting is
held. The shape of the VCF is classified as wedge, bicon-
cave or crush, depending on whether anterior, middle or
posterior portion of vertebral body is most diminished in
height. The grade of VCF is classified as a percentage of
height reduction in mild (15–25%), moderate (25–40%)
and severe (>40%).
Percutaneous vertebroplasty group
The pre-procedural work-up consists of: ECG, X-thorax
and blood sampling. One hour prior to the procedure 2 g
cefazolin is administered intravenously as prophylaxis.
All vertebroplasties are performed by experienced radiol-
ogists in the angio suite under optimal (anteroposterior
and lateral) fluoroscopic guidance. The procedure takes
place under sterile conditions. Local anaesthesia is admin-
istered from skin to the periosteum of the targeted pedicle.
In two centres patients also receive fentanyl intravenously
prior to the procedure. In one centre patients get propofol
as intravenous anaesthetic.
Polymethylmetacrylate bone cement (Osteo-Firm®,
COOK Medical, Bloomington, Indiana, USA) is injected
under continuous fluoroscopic imaging guidance using
1,0 cc syringes and 11 or 13 Gauge bone biopsy needles.
The amount of injected cement in each treated vertebral
body and any cement leakage is recorded. After the proce-
dure a computed tomography (CT) scan of the treated ver-
tebral bodies is performed to identify cement leakage or
other possible local complications.
All patients are put on osteoporosis medication, such as
bisphosphonates together with supplemental calcium
and vitamin D.
Conservative therapy group
Conservative therapy mainly consists of OPM. The
internist optimizes the use of analgesics in ascending
order: (1) Paracetamol (acetaminophen), (2) Tramadol,
(3) Tramadol and Paracetamol, (4) Morphine. Non Ster-
oid Anti Inflammatory Drugs (NSAID) are only prescribed
if patients are intolerant for opiate-derivatives or in situa-
tions when already used. Corrections in dose and classifi-
cation of pain medication are made if necessary by the
internist. In most cases physiotherapy is prescribed. All
patients receive osteoporosis medication, such as bisphos-
phonates together with supplemental calcium and vita-
min D.
Clinical follow-up
All patients are asked to fill out standard questionnaires
before and at one day, one week, one month, three
months, six months and twelve months after PV or when
conservative treatment is started by the internist.Page 3 of 5
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after one day) consist of the VAS score, QOL Question-
naire of the European Foundation for Osteoporosis
(Qualeffo), EQ-5D, Roland Morris Disability (RMD)
Questionnaire. Cost-effectiveness is assessed and ques-
tions concerning use of pain medication, pain location,
pain type are included.
The VAS score is a pain score ranging from 0 (no pain) to
10 (worst pain ever) [22]. The Qualeffo is developed spe-
cifically for patients with osteoporosis [23]. This question-
naire consists of 41 questions about: pain, physical
function, social function, general health perception and
mental function. The Qualeffo score ranges from 0 (best
quality of life) to 100 (worst quality of life).
The RMD questionnaire is a disability questionnaire that
measures the functional status of patients with back pain
[24,25].
EQ-5D is a standardized instrument utilized as a measure
of health related quality of life outcome [26]. Further-
more, EQ-5D is one of a few measures recommended for
use in cost-effectiveness analyses by the Washington Panel
on Cost Effectiveness in Health & Medicine as well as in
National guidelines in economic evaluation [27].
Procedural costs, other medical treatment and visits to
alternative medical specialists, GP's and physical thera-
pists are recorded and compared between groups. The
questionnaire at day one post-procedural is a short ques-
tionnaire with a VAS score and questions about pain med-
ication use, pain location, pain type and cost-
effectiveness. All patients visit the internist at one and
three months follow-up. All patients receive a pain diary.
Patients are asked to fill out the VAS score and use of anal-
gesics is recorded on a daily basis up until one month after
randomization.
Imaging follow-up
At one, three and twelve months follow-up an X ray of the
thoracic and lumbar spine, including antero-posterior
and lateral views, is performed and compared to the X-ray
at baseline. Secondary fractures are recorded. The shape
and grade of every VCF is scored by two radiologists using
the visual semiquantitative system according to Genant
[21]. When there is disagreement between both observers
a consensus meeting is held.
Sample size considerations
Based on pilot data and literature we expect a difference of
25% in significant pain relief. If we assume that 20% with-
draws from intervention we need approximately 100
patients in each group (α = 0.05 and β = 0.20).
Statistical analysis
The data will be analysed according to the intention-to-
treat principle. Standard statistical techniques will be used
to describe characteristics of patients in both groups. We
will compare baseline characteristics in the two treatment
groups and if incomparability appears, we will in second-
ary analysis adjust for differences. The main outcome, sig-
nificant pain relief will be compared with the Kaplan
Meier survival analysis. Adjustment for possible baseline
incomparability will be done with the Cox proportional
hazards model.
A cost-effectiveness analysis will be performed at four
weeks and one year. Medical costs, time without burden-
some pain and quality adjusted survival time will be com-
pared. Bootstrapping and in case long-term modelling is
required for comprehensive evaluation multivariate prob-
abilistic sensitivity analysis will be used to evaluate uncer-
tainty in the cost-effectiveness ratios.
Conclusion
To the best of our knowledge the VERTOS II study is the
first consistent RCT designed to assess the cost-effective-
ness of PV compared to conservative therapy in patients
with an acute osteoporotic VCF with mid-term follow-up.
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